2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
14
Carcinoid Tumor
5
Gastro-enteropancreatic neuroendocrine tumor
4
Acromegaly
4
Serotonin Syndrome
2
Pituitary Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Hepatocellular
2
Prostatic Neoplasms
1
Pheochromocytoma
1
Peritoneal Neoplasms
1
Paraganglioma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neuroendocrine Tumors in Lung
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Intestinal Obstruction
1
Growth Hormone-Secreting Pituitary Adenoma
1
Gigantism
1
Gastrointestinal Neoplasms
1
Flushing
1
Endocrine Tumors
1
Diarrhea
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Carcinoid Heart Disease
1
Adenoma, Islet Cell
1
Interventions
3-Iodobenzylguanidine
14
Temozolomide
6
lutetium Lu 177 dotatate
5
gallium Ga 68 dotatate
4
anlotinib
4
Specimen Handling
4
Everolimus
4
Radiotherapy
3
Phenoxybenzamine
3
Magnetic Resonance Spectroscopy
3
Doxorubicin
3
6-fluorodopamine
3
3-fluorobenzylguanidine
3
pegfilgrastim
2
olaparib
2
fluorodopa F 18
2
cabozantinib
2
belzutifan
2
Nivolumab
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Doxazosin
2
Dexmedetomidine
2
Capecitabine
2
Biopsy
2
Axitinib
2
Adrenalectomy
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
lanreotide
×
Clear all
NCT03946527
2026-03-02
LAMPARA
Columbia University
Phase 2
Active not recruiting
10 enrolled